lated folates (quantified as the sum of 5,10CHϭTHF and 5-or 10CHOTHF) made up, on average, 30% (range, 0 -69%) of the TF in erythrocytes of individuals with the T/T genotype. The preliminary results for individuals with the C/T genotype (n ϭ 5) indicated that erythrocytes contained only 5CH 3 THF polyglutamates. No THF was detected in the erythrocytes of individuals with either genotype. The discrepancies in findings between our work and that of Bagley and Selhub (12 ) , i.e., we found small amounts of formylated folates in individuals with the C/C genotype and significant amounts of THF in individuals with the T/T genotype, might be explained by the difference in folate extraction. Bagley and Selhub (12 ) extracted frozen erythrocytes at high pH to prevent enzymatic deconjugation of folate polyglutamates. We used WB lysates generated at low pH (4.0) to obtain folate monoglutamates by the action of plasma pteroylpoly-␥-glutamate hydrolase. Although this is the generally recommended and clinically used procedure for WB folates, it is conceivable that folate metabolism takes place during the lysis process. As a result, some folate forms could be found in conventionally prepared WB lysates that might not be present in native erythrocytes. The THF we find is most likely the dissociation product of 5,10-methylenetetrahydrofolic acid losing the C-1 group.
We analyzed ϳ100 paired serum and WB lysate samples to assess what proportion of folates found in WB originates from serum. In general, we found no FA in WB lysates with the exception of those from two individuals who had serum FA concentrations Ͼ25 nmol/L, which spilled over into the WB lysate. Serum did not have quantifiable amounts of THF or 5,10CHϭTHF. On average, ϳ95% each of 5CH 3 THF and 5CHOTHF in WB lysates originated from erythrocytes, whereas the rest originated from serum. All of the THF and 5,10CHϭTHF found in WB lysates originated from erythrocytes.
The presented method measures folate monoglutamates only. If deconjugation of polyglutamates is incomplete, the TF concentration will be underestimated. Our findings on folate extraction from WB and the comparability of results obtained with different methods will be presented in a subsequent report. This is the first reported method for measuring intact folate monoglutamates in serum and conventionally prepared WB lysates by LC/MS/MS using automated highthroughput SPE. The method displays excellent sensitivity and satisfactory precision, accuracy, and stability of folates during the 5-h SPE procedure. The specificity of this method is a clear advantage when it comes to quantifying individual folate forms. It can be a disadvantage when measurement of TF is of interest because the only folate forms measured are those that one is aware of. However, this highly specific method has a high potential of becoming a candidate reference method and helping to establish a standard reference material, which ultimately is needed to standardize clinical assays. The method's automation and high sample throughput make it attractive for future use in clinical laboratories when further studies of the method have been completed. Measurement of plasma metanephrine and normetanephrine concentrations has recently been acknowledged as one of the leading tests for the diagnosis of the neuroendocrine tumor, pheochromocytoma (1 ) . The occurrence of the tumor is rare, and it is often difficult to diagnose. The wide spectrum of signs and symptoms includes hypertension, headaches, and diaphoresis. Located primarily in the adrenal gland, these tumors produce excess catecholamines and their metabolites. Assays have been developed to measure catecholamines and metanephrines in both plasma and urine. Although tests for all of these compounds can be diagnostically useful, measurement of metanephrine and normetanephrine in plasma has been reported as a particularly sensitive and specific indicator of the disease. The utility of the test is limited by uncertainty of the predictive value of measured concentrations. This is attributable in part to ambiguity in published reference intervals for these analytes. Lenders et al. (1 ) reported upper reference limits of 0.3 nmol/L for plasma metanephrine and 0.6 nmol/L for normetanephrine, whereas a reference laboratory (2 ) reported values Ͻ0.5 nmol/L for metanephrine and Ͻ0.9 nmol/L for normetanephrine as within the reference interval.
In this study, we established a reference interval by measuring metanephrine and normetanephrine concentrations in plasma collected from 120 volunteers after obtaining informed consent. Reference individuals (53 females and 67 males; age range, 20 -73 years) fasted for 12 h before sampling. Interviews were conducted to excuse individuals taking medications, particularly for hypertension. All participants were sitting upright as their blood was collected by needlestick. The whole blood, in EDTA, was stored at 2-8°C until it was centrifuged within a few hours after collection. Plasma was separated and stored at Ϫ70°C until analysis.
The conditions under which the volunteers were prepared and blood was collected were selected based on evaluation of studies in the literature. Volunteers were fasting to eliminate the interference of dietary constituents in the HPLC analysis, as observed by Lenders et al. (1 ) . For this reason, medical practitioners are advised to instruct patients to fast for 12 h before blood collection for plasma metanephrine analysis. Additionally, as published elsewhere, plasma catecholamine concentrations are posture-dependent, but plasma metanephrine concentrations are not significantly altered if a patient is sitting or lying supine (3 ).
Metanephrines were assayed by a procedure similar to the method developed by Lenders et al. (4 ) . Contaminants were removed by solid-phase extraction with BondElut ® AccuCAT columns (Varian, Inc.). Plasma (1 mL) was applied to the columns with an internal standard, 4-hydroxy-3-methoxybenzylamine. The analytes were eluted with 10% ammonium hydroxide in methanol (1:3 by volume), and the eluate was evaporated to dryness under nitrogen at 37°C. The residue was reconstituted in 115 L of 0.2 mol/L acetic acid, and 80 L was injected for separation by reversed-phase HPLC. The mobile phase consisted of acetonitrile (70 mL/L) in sodium phosphate buffer, pH 3.25. The mobile phase flow rate was 1.2 mL/min. The analytical column was a LUNA C 18 reversed-phase column [250 ϫ 4.6 mm (i.d.); 5-m bead size; Phenomenex]. The ESA 580 pump, 540 autosampler, and ESA 316 CoulArray Detector were from ESA, Inc. The analytes were detected coulometrically with a conditioning cell (5021; ESA) electrode at 410 mV and an analytical cell (5011; ESA) at Ϫ310 mV. All of the compounds were separated and detected within 20 min. The retention times for metanephrine, normetanephrine, and the internal standard were 9.5, 7.1, and 11.7 min, respectively. The total run-time was extended to 31 min because of lateeluting compounds. A five-point calibration curve with the internal standard was used to calibrate the method. Analytes were quantified by comparison of the peak height and internal standard ratio with the calibration curve.
A range of concentrations of metanephrine and normetanephrine was injected to determine the linearity of the method. The recovery of this method was established by analyzing solutions of known concentrations and plotting the known samples against the values acquired by the analysis. Over the linear range of the method, recovery for metanephrine was 100.3% of the expected amount and recovery for normetanephrine was 102.5%. Imprecision was determined by assaying each of three quality-control solutions in duplicate on 15 different days. This method was compared with a similar HPLC method (with cation-exchange, solid-phase extraction, and electrochemical detection) at a reference laboratory. Thirty samples, with concentrations spanning the linear range of the method, were analyzed by both methods, and data were evaluated by plotting the points for comparison. For metanephrine, the standard error of the estimate (S y͉x ) was 0.20 nmol/L, unfortunately high because of a difference in detection limits for the two methods. Results Ͼ0.15 nmol/L were calculated by this method, but the reference laboratory did not quantify results Ͻ0.2 nmol/L. The standard error of the estimate was 0.28 nmol/L for normetanephrine. The performance characteristics data are summarized in Table 1 . Acetaminophen, caffeic acid, and ephedrine did not interfere with this assay at physiologic concentrations.
The reference interval data were analyzed according to the NCCLS guideline for determining reference values (5 ) . Data points were placed in decreasing order and then evaluated to eliminate outliers. The distribution of results was nongaussian for both analytes (Fig. 1) . The central 95% of the data were taken as the reference interval for each analyte.
Results ranged from Ͻ0.15 to 0.37 nmol/L for metanephrine and from Ͻ0.16 to 0.94 nmol/L for normetanephrine. Fifty-three percent of the metanephrine data fell below 0.15 nmol/L, the limit of quantification for this assay. The mean and median values were 0.16 and 0.15 nmol/L, respectively, for metanephrine and 0.40 and 0.36 nmol/L for normetanephrine. With 90% confidence, the upper reference limits were determined to be 0.29 nmol/L for metanephrine and 0.77 nmol/L for normetanephrine.
The reference intervals calculated in this study were comparable to those reported previously in the literature and fall between those of the two cited reports (1, 2 ) .
Reference interval values are included in Table 1 .
We analyzed patient results over a 6-month period with the newly determined reference limits. Of 1657 patient samples, 20.0% were increased with our upper reference limit, 0.29 nmol/L; 17.6% of the metanephrine values were increased by the criterion of 0.5 nmol/L suggested by Sawka et al. (2 ) . For normetanephrine, 25.1% were increased based on our upper reference limit of 0.77 nmol/L, and 4.6% of the values were increased according to the upper reference limit of 0.9 nmol/L reported by Sawka et al. (2 ) .
As reported by Kudva et al. (6 ) , cutoff concentrations for some analytes used to diagnose pheochromocytoma are adjusted to approximately twice the upper limit found in a healthy population. This technique has been found to provide optimal specificity while maintaining acceptable sensitivity. Although the authors do not state that this method was used to establish reference limits for plasma metanephrine and normetanephrine concentrations, it is interesting to note that this would account for the differences between reference limits used by Sawka et al. (2 ) and those determined in our study of a healthy population as well as those used by Lenders et al. (1 ) . Definition of a positive result as a multiple of the upper limit of the 95% population reference interval may be of value in minimizing false-positive results and is consistent with the accepted medical use of biochemical testing to aid clinical judgment in the evaluation of pheochromocytoma (7 ) . Adoption of lower reference limits for metanephrine and normetanephrine, such as those determined in our study, may lead to an increase in reported positive results. In this case, additional biochemical testing and radiologic imaging will be required for the diagnostic confirmation of pheochromocytoma. Although false-positive tests may lead to increased costs to the patient, false-negative results are far more destructive and are potentially fatal.
This study established concise numerical limits for metanephrine and normetanephrine concentrations in the plasma of a population of healthy individuals with no indication of disease. The results of the study may be of value in the interpretation of plasma metanephrine concentrations used to support a clinical diagnosis of pheochromocytoma.
Research for this work was supported by the ARUP Institute for Clinical and Experimental Pathology. Gene expression profiling using microarrays has revolutionized the analysis of biological samples. In clinical applications, microarray data have been used to successfully distinguish among patients exhibiting similar symptoms (1, 2 ) . Early demonstrations of this power were in the diagnosis of subtypes of acute leukemia (3 ) and diffuse large B-cell lymphomas (4 ), and such analyses are gradually gaining acceptance for diagnostic and prognostic applications (5) (6) (7) . Investigators are currently accumulating microarray data for a broad assortment of such studies but are limited by the requirement of fresh/frozen tissues for sample preparation and labeling (8 ) . This limitation requires the accumulation of fresh samples throughout the course of the disease, which may involve years of monitoring. However, formalin-fixed, paraffinembedded (FFPE) tissues are widely available and have the advantage of a known patient outcome and drug response history. RNAs derived from these samples are commonly badly degraded and have not been useful for conventional microarray studies (9, 10 ) . We applied a novel expression assay to simultaneously monitor 502 cancer-related genes in RNAs derived from FFPE samples, using microarrays assembled on fiber optic bundles. Our results suggest that this approach can be used for extending microarray analyses to RNAs derived from archival tissue samples.
Distribution of results for metanephrine
We have recently developed a gene expression method called the DASL TM assay (cDNA-mediated annealing, selection, extension, and ligation) (11 ) . This assay targets gene-specific sequences, using pools of chimeric query oligonucleotides. The oligonucleotides all share common primer landing sites so that once the upstream oligonucleotide is extended and ligated to the downstream oligonucleotide, an amplifiable product is generated. One PCR primer pair is used to amplify all of the amplifiable templates and generate amplicons of similar size (ϳ100 bp). This uniformity minimizes potential bias during amplification of many different targets. Currently, the DASL assay can be multiplexed to monitor hundreds of genes (11 ) .
To allow the use of universal microarrays, the downstream query oligonucleotides also contain a unique address sequence that is associated with each gene. This address sequence allows the amplified product, which is labeled during PCR with a fluorescent primer, to hybridize to a microarray bearing the complementary address sequences. This feature provides ready flexibility: to change the genes being monitored, the address sequences can be reassigned and the query oligonucleotide pool resynthesized, using the same arrays.
Finally, the cDNA synthesis step is performed with both oligo(dT) and random priming, which frees the assay from dependence on an intact polyA tail, unlike the usual T7 promoter-oligo(dT) priming method for microarray sample preparation (12 ) . The use of random hexamers or nonamers in the cDNA synthesis allows representation of targeted cDNA sequences despite RNA degradation. Less than 50% of target probes in FFPE samples were detected when only oligo(dT) primer was used for cDNA synthesis, compared with the use of both oligo(dT) and random primers.
To monitor gene expression in FFPE samples, we prepared RNA from 5-m human tissue sections mounted on microscope slides, obtained from BioChain Institute according to an Institutional Review Board-approved protocol. Briefly, the slides were deparaffinized in xylenes, and tissue samples were then scraped off with razor blades and held in xylenes until subsequent processing. RNA was extracted by use of the High Pure RNA Paraffin Kit (Roche Applied Science) and quantified by use of RiboGreen (Molecular Probes). When measured on Bioanalyzer (Agilent) RNA Pico Chips, the size of the RNA fragments ranged from 100 to Ͼ500 nucleotides, with a peak maximum at ϳ130 nucleotides. On average, 1-2 g of total RNA was isolated from five 5-m tissue sections. For each sample, 200 ng of total RNA was converted to cDNA and processed in the DASL assay as described previously (11, 13 ) . Oligonucleotides targeting 502 cancer-related genes were used in these experiments, at a density of three nonoverlapping probes per gene, giving a 1506-plex measurement for each sample. Our previous study showed that three probes per gene lend the assay sufficient sensitivity and reproducibility for quantitative detection of differential expression in FFPE tissues (13 ) . Mean signal values were computed for each gene by determining the mean signal for the three representative probes (11 ) . Because DASL uses random priming in the cDNA synthesis, the probes can be designed to target any unique regions of the gene without the need to limit the selection of optimal probes to the 3Ј end of transcripts.
We profiled 16 FFPE samples of four tissue typesprostate, colon, breast, and lung-with each tissue represented by one nondiseased and several cancer samples. As shown in Fig. 1 , the DASL assay gave highly reproducible intensity measurements for FFPE samples preserved for 1.5-3 years. The correlations (r 2 ) between the
